Christopher Kroeger

Chris is the CEO and cofounder of MapLight Therapeutics.

Chris brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, combined with the expertise of a physician and scientist. Chris previously served as the CEO of Cardioxyl Pharmaceuticals, leading a team that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Chris was also previously the CEO of OvaScience, a publicly traded female fertility company where he led a turnaround effort resulting in a successful merger with Millendo Therapeutics. Earlier in his career, Chris led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies, and held positions at Genzyme and Decision Resources.

Chris earned his bachelor’s in Biology from Harvard University and his Doctor of Medicine from Stanford University School of Medicine. He completed his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. Chris also holds his MBA from Harvard Business School. He currently serves on the Board of Directors of CardioFocus and Cantex Pharmaceuticals.